According to the company, from the €2.6m grant it will receive €215.000, which would be used in its ongoing three year project of determining the clinical value of implementing a Europe-wide acceptable HLA mismatch program, which will aid in safer transplantations in highly sensitized patients all over Europe.
Under the project, AbSorber will use its newly developed The XM-ONE crossmatch test, which not only helps to detect the anti-endothelial antibodies, but also determines if the antibodies are complement fixing or non-complement fixing, which is another risk factor.
Th firm said it is also planning to develop a modified version of XM-ONE.
Allenex and AbSorber CEO Anders Karlsson said the firm is happy to team up with the EUROSTAM consortium
"This is a strong recognition of the product XM-ONE as well as the research and development done within AbSorber. It is encouraging for our development team to be recognized for the innovation of XM-ONE,"Karlsson added.
"We look forward to further develop XM-ONE into a transplantation product with a proven clinical value in cooperation with leading European transplantation centers."